Yorvipath

The active substance in Yorvipath, palopegteriparatide, is changed in the body into teriparatide, a shortened form of PTH. Teriparatide replaces the missing hormone in patients with hypoparathyroidism, acting through bone tissue and the kidneys to help restore calcium levels.

Yorvipath is given as an injection under the skin using a pre-filled pen. The medicine can only be obtained with a prescription. Treatment should be started and monitored by a doctor or a qualified healthcare professional experienced in the diagnosis and management of patients with chronic hypoparathyroidism.

For more information about using Yorvipath, see the package leaflet or contact your doctor or pharmacist.

One main study involving 84 patients with hypoparathyroidism showed that Yorvipath was effective at keeping blood calcium levels within the normal range, compared with placebo. Around 79% (48 out of 61) of patients given Yorvipath for 26 weeks achieved normal blood calcium levels, no longer needed standard treatments (active vitamin D and high-dose calcium supplements) and were on a stable dose of the medicine. This compared with 5% (1 out of 21) of patients given placebo.

For the full list of side effects and restrictions with Yorvipath, see the package leaflet.

The most common side effects with Yorvipath (which may affect more than 1 in 10 people) include injection site reactions, headache and paraesthesia (unusual sensations like pins and needles).

Yorvipath must not be used in patients who have pseudohypoparathyroidism, a condition in which the body does not adequately respond to the parathyroid hormone produced by the body.

Yorvipath replaces the missing parathyroid hormone in patients with chronic hypoparathyroidism, and the results of the main study showed that most patients given the medicine had blood calcium levels within the normal range and no longer needed therapeutic doses of calcium supplements and active vitamin D to control their disease. In addition, side effects are considered to be manageable.

The European Medicines Agency therefore decided that Yorvipath’s benefits are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yorvipath have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Yorvipath are continuously monitored. Side effects reported with Yorvipath are carefully evaluated and any necessary action taken to protect patients.

Yorvipath received a marketing authorisation valid throughout the EU on 17 November 2023.